Metagenomi Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
MGX$0.70-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(50,541) | $(44,947) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 4,820 | 6,149 |
| Depreciation | 2,540 | 2,693 |
| Loss on fixed assets write-off | — | 181 |
| Non-cash lease expense | 2,690 | 2,664 |
| Accretion of discounts on available-for-sale marketable securities | (555) | (1,825) |
| Amortization of non-cash collaboration revenue | — | (87) |
| Change in fair value of long-term investments | — | 1,292 |
| Impairment of right of use assets | 634 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 305 | 384 |
| Prepaid expenses and other assets | 783 | 2,687 |
| Accounts payable | 1,114 | 2,284 |
| Deferred revenue | (491) | (10,417) |
| Accrued expenses and other current liabilities | 886 | (2,476) |
| Operating lease liabilities | (2,937) | (2,818) |
| Other non-current liabilities | 64 | 143 |
| Net cash used in operating activities | (40,688) | (44,093) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (150) | (415) |
| Proceeds from sale of property and equipment | — | 37 |
| Purchases of available-for-sale marketable securities | (40,655) | (40,796) |
| Maturities of available-for-sale marketable securities | 77,959 | 84,974 |
| Net cash provided by investing activities | 37,154 | 43,800 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock under the ESPP | 74 | 109 |
| Payment of deferred financing costs | (34) | (352) |
| Net cash provided by (used in) financing activities | 40 | (243) |
| Net decrease in cash, cash equivalents and restricted cash | (3,494) | (536) |
| Cash, cash equivalents and restricted cash at beginning of period | 46,915 | 32,634 |
| Cash, cash equivalents and restricted cash at end of period | $43,421 | $32,098 |
| Supplemental disclosure of non-cash information | ||
| Deferred finance issuance costs included in accounts payable, accrued expenses and other current liabilities | $2 | $183 |
| Reconciliation of cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents | $39,028 | $26,850 |
| Restricted cash | 4,393 | 5,248 |
| Cash, cash equivalents and restricted cash at end of period | $43,421 | $32,098 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.